Abstract
Ornithine decarboxylase (ODC) is a rate-limiting enzyme for the synthesis of polyamines (PAs). PAs are required for proliferation, and increased ODC activity is associated with cancer and neural over-proliferation. ODC levels and activity are therefore tightly regulated, including through the ODC-specific inhibitor, antizyme AZ1. Recently, ODC G84R has been reported as a partial loss-of-function variant that is associated with intellectual disability and seizures. However, G84 is distant from both the catalytic center and the ODC homodimerization interface. To understand how G84R modulates ODC activity, we have determined the crystal structure of ODC G84R in both the presence and the absence of the cofactor pyridoxal 5-phosphate. The structures show that the replacement of G84 by arginine leads to hydrogen bond formation of R84 with F420, the last residue of the ODC C-terminal helix, a structural element that is involved in the AZ1-mediated proteasomal degradation of ODC. In contrast, the catalytic center is essentially indistinguishable from that of wildtype ODC. We therefore reanalyzed the catalytic activity of ODC G84R and found that it is rescued when the protein is purified in the presence of a reducing agent to mimic the reducing environment of the cytoplasm. This suggests that R84 may exert its neurological effects not through reducing ODC catalytic activity but through misregulation of its AZ1-mediated proteasomal degradation.
| Original language | English |
|---|---|
| Pages (from-to) | 34665-34675 |
| Number of pages | 11 |
| Journal | ACS Omega |
| Volume | 7 |
| Issue number | 38 |
| DOIs | |
| State | Published - Sep 27 2022 |
Funding
This work was supported in part by the Canada 150 Research Chairs program grant C150-2017-00015 (B.D.), the Canada Foundation for Innovation grant CFI-37589 (B.D.), the National Institutes of Health grant 1R01GM120600 (B.D.), the Canadian Natural Science and Engineering Research Council grant DG-RGPIN-2019-05637 (B.D.), the Van Andel Institute (K.M.), and by the Spectrum Health-Michigan State University Alliance Corporation funds (A.S.B.). The use of the Advanced Photon Source (APS), an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science by Argonne National Laboratory, was supported by the U.S. DOE under contract DEAC02-06CH11357. UltraScan supercomputer calculations were supported through the NSF/XSEDE grant TG-MCB070039N (to B.D.) and University of Texas grant TG457201 (to B.D.). Computational resources and support from the University of Montana’s Griz Shared Computing Cluster (GSCC) contributed to this research.
| Funders | Funder number |
|---|---|
| TG457201 | |
| Van Andel Institute | |
| TG-MCB070039N | |
| 1R01GM120600 | |
| DEAC02-06CH11357 | |
| Argonne National Laboratory | |
| DG-RGPIN-2019-05637 | |
| Canada Foundation for Innovation | CFI-37589 |
| C150-2017-00015 |